Federal Register / Vol. 83, No. 155 / Friday, August 10, 2018 / Notices 39763 

Washington, Center for Drug Evaluation 

and Research, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Silver Spring, MD 20993–0002, 

301–796–1019, tisha.washington@

fda.hhs.gov no later than September 4, 

2018. 

Requests for Oral Presentations: 

During online registration you may 

indicate if you wish to present at the 

public comment session, and which 

topic(s) you wish to address. We will do 

our best to accommodate requests to 

make public comments. Individuals and 

organizations with common interests are 

urged to consolidate or coordinate their 

presentations, and request time for a 

joint presentation. Following the close 

of registration, we will determine the 

amount of time allotted to each 

presenter and the approximate time 

each oral presentation is to begin, and 

will select and notify participants by 

September 5, 2018. All requests to make 

oral presentations must be received by 

the close of registration on September 4, 

2018. If selected for presentation, any 

presentation materials must be emailed 

to Tisha Washington (see FOR FURTHER

INFORMATION CONTACT) no later than 

close of business, September 6, 2018. No 

commercial or promotional material 

will be permitted to be presented or 

distributed at the public workshop. 

Streaming Webcast of the Public 

Workshop: This public workshop will 

also be webcast. The webcast link will 

be available on the following web page 

5 days before the workshop at: https:// 

www.fda.gov/Drugs/NewsEvents/ 

ucm611203.htm. 

If you have never attended a Connect 

Pro event before, test your connection at 

https://collaboration.fda.gov/common/ 

help/en/support/meeting_test.htm. To 

get a quick overview of the Connect Pro 

program, visit https://www.adobe.com/ 

go/connectpro_overview. FDA has 

verified the website addresses in this 

document, as of the date this document 

publishes in the Federal Register, but 

websites are subject to change over time. 

Transcripts: Please be advised that as 

soon as a transcript of the public 

workshop is available, it will be 

accessible at https://

www.regulations.gov. It may be viewed 

at the Dockets Management Staff (HFA– 

305), Food and Drug Administration, 

5630 Fishers Lane, Rm. 1061, Rockville, 

MD 20852. A link to the transcript will 

also be available on the internet at 

https://www.fda.gov/Drugs/NewsEvents/ 

ucm611203.htm. 

Dated: August 6, 2018. 

Leslie Kux, 

Associate Commissioner for Policy. 

[FR Doc. 2018–17130 Filed 8–9–18; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

HHS Approval of Entities That Certify 

Medical Review Officers 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: This notice publishes a list of 

the Department of Health and Human 

Services (HHS) approved Medical 

Review Officers certification entities. 

The HHS Mandatory Guidelines for 

Federal Workplace Drug Testing 

Programs (Mandatory Guidelines), 

applicable on October 1, 2017, 

addresses the role and qualifications of 

Medical Review Officers (MROs) and 

HHS approval of entities that certify 

MROs. 

FOR FURTHER INFORMATION CONTACT: 

Sean J. Belouin, Pharm.D., CAPT, 

United States Public Health Service, 

Senior Pharmacology and Regulatory 

Policy Advisor, Substance Abuse and 

Mental Health Services Administration, 

5600 Fishers Lane, Room 16N06D, 

Rockville, Maryland 20857; Telephone: 

(240) 276–2716; Email: sean.belouin@

samhsa.hhs.gov. 

SUPPLEMENTARY INFORMATION: Subpart 

M—Medical Review Officer (MRO), 

Section 13.2 of the Mandatory 

Guidelines, ‘‘How are nationally 

recognized entities or subspecialty 

boards that certify MROs approved?’’ 

states as follows: ‘‘All nationally 

recognized entities or subspecialty 

boards which seek approval by the 

Secretary to certify physicians as MROs 

for federal workplace drug testing 

programs must submit their 

qualifications, a sample examination, 

and other necessary supporting 

examination materials (e.g., answers, 

previous examination statistics or other 

background examination information, if 

requested) (OMB Control No.: 0930– 

0158). Approval will be based on an 

objective review of qualifications that 

include a copy of the MRO applicant 

application form, documentation that 

the continuing education courses are 

accredited by a professional 

organization, and the delivery method 

and content of the examination. Each 

approved MRO certification entity must 

resubmit their qualifications for 

approval every two years. The Secretary 

shall publish at least every two years a 

notice in the Federal Register listing 

those entities and subspecialty boards 

that have been approved. This notice is 

also available on the internet at http:// 

www.samhsa.gov/workplace/drugtesting.’’ 

HHS has completed its review of 

entities that certify MROs, in 

accordance with requests submitted by 

such entities to HHS. 

The HHS Secretary approves the 

following MRO certifying entities that 

offer MRO certification through 

examination: 

American Association of Medical 

Review Officers (AAMRO), P.O. Box 

12873, Research Triangle Park, NC 

27709, Phone: (919) 489–5407, Fax: 

(919) 490–1010, Email: bbrandon@

aamro.com, website: http://

www.aamro.com/. 

Medical Review Officer Certification 

Council (MROCC), 3231 S. Halsted St, 

#167, Chicago, IL 60608, Phone: (847) 

631–0599, Fax: (847) 483–1282, 

Email: mrocc@mrocc.org, website: 

http://www.mrocc.org/. 

DATES: HHS approval is effective July 

31, 2018. 

Alex M. Azar II, 

Secretary. 

[FR Doc. 2018–17184 Filed 8–9–18; 8:45 am] 

BILLING CODE 4162–20–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Alcohol Abuse 

and Alcoholism; Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Advisory 

Council on Alcohol Abuse and 

Alcoholism. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 


daltland on DSKBBV9HB2PROD with NOTICES
39764 Federal Register / Vol. 83, No. 155 / Friday, August 10, 2018 / Notices 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Council on Alcohol Abuse and Alcoholism. 

Closed: September 13, 2018. 

Time: 9:00 a.m. to 9:45 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute on Alcohol Abuse and 

Alcoholism, 6700–B Rockledge Drive, 

Conference Rooms A & B, Bethesda, MD 

20817. 

Open: September 13, 2018. 

Time: 9:45 a.m. to 3:00 p.m. 

Agenda: Presentations and other business 

of the Council. 

Place: National Institutes of Health, 

National Institute on Alcohol Abuse and 

Alcoholism, 6700–B Rockledge Drive, 

Conference Rooms A & B, Bethesda, MD 

20817. 

Contact Person: Abraham P. Bautista, 

Ph.D., Executive Secretary, National 

Advisory Council, National Institute on 

Alcohol Abuse and Alcoholism, National 

Institutes of Health, 6700–B Rockledge Drive, 

Suite 1458, MSC 6902, Bethesda, MD 20892, 

301–443–9737 bautista@mail.nih.gov. 

Information is also available on the 

Institute’s/Center’s home page: https://

www.niaaa.nih.gov/news-events/meetingsevents-exhibits, where an agenda and any 

additional information for the meetings will 

be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.271, Alcohol Research 

Career Development Awards for Scientists 

and Clinicians; 93.272, Alcohol National 

Research Service Awards for Research 

Training; 93.273, Alcohol Research Programs; 

93.891, Alcohol Research Center Grants; 

93.701, ARRA Related Biomedical Research 

and Research Support Awards, National 

Institutes of Health, HHS) 

Dated: August 6, 2018. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–17107 Filed 8–9–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; ADC P30 

Review. 

Date: September 17–18, 2018. 

Time: 2:00 p.m. to 1:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Garden Inn, 7301 Waverly 

St., Bethesda, MD 20814. 

Contact Person: Maurizio Grimaldi, MD, 

Ph.D., Scientific Review Officer, National 

Institute on Aging, National Institutes of 

Health, 7201 Wisconsin Avenue, Room 

2C218, Bethesda, MD 20892, 301–496–9374, 

grimaldim2@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: August 6, 2018. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–17103 Filed 8–9–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Chronic Pain: The Science of 

Complementary and Integrative Health 

Approaches 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: This symposium on 

September 11, 2018, sponsored by the 

National Center for Complementary and 

Integrative Health, will bring leading 

researchers to discuss the science and 

potential uses of complementary and 

integrative health approaches in treating 

chronic pain. 

DATES: The meeting will be held on 

September 11, 2018, from 8:30 a.m. to 

5:30 p.m. 

ADDRESSES: The meeting will be held at 

the Boston Convention and Exhibition 

Center, 415 Summer Street, Boston, MA 

02210. 

FOR FURTHER INFORMATION CONTACT: For 

information concerning this meeting, 

see the NCCIH website, https://

nccih.nih.gov/chronic-pain-symposium2018?nav=govd, the 17th World 

Congress on Pain website, https://

www.iaspworldcongressonpain.org/ 

program/current-satellite-symposia/ 

#toggle-id-3, or contact Dr. Wen Chen, 

Acting Branch Chief and Program 

Director, Basic and Mechanistic 

Research, Division of Extramural 

Research, National Center for 

Complementary and Integrative Health, 

6707 Democracy Boulevard, Suite 401, 

Bethesda, MD 20892, telephone: 301– 

451–3989; email: when.chen2@nih.gov. 

SUPPLEMENTARY INFORMATION: This 

symposium, sponsored by the National 

Center for Complementary and 

Integrative Health, will bring leading 

researchers from multiple disciplines to 

discuss the science and potential uses of 

complementary and integrative health 

approaches in treating chronic pain. The 

symposium will highlight current 

concerns regarding the opioid epidemic 

and the potential roles of 

complementary and integrative health 

approaches in addressing this crisis. 

The objectives of the symposia are to: 

Present the past, present, and future of 

natural products research and pain 

management, focusing on our current 

understanding of the ascending and 

descending neural mechanisms by 

which different natural products may 

contribute to analgesia; ascertain the 

mechanisms by which a variety of mind 

and body approaches may modulate 

pain; and discuss translational potential 

for complementary and integrative 

approaches for individual-based chronic 

pain management. 

Interested individuals can register for 

the symposia at: https://www.iaspworld

congressonpain.org/registration/. Once 

you have created a free IASP account, 

you can choose to register for a Satellite 

Symposium only. Choose the Satellite 

Symposium ‘‘Chronic Pain: The Science 

of Complementary and Integrative 

Health Approaches.’’ The registration 

fee is $20 for the 1-day symposium. 

Dated: August 6, 2018. 

David Shurtleff, 

Acting Director, National Center for 

Complementary and Integrative Health, 

National Institutes of Health. 

[FR Doc. 2018–17118 Filed 8–9–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Alcohol Abuse 

and Alcoholism; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 


daltland on DSKBBV9HB2PROD with NOTICES